Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Angela Dispenzieri, MD, Eftathios Kastritis, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM, Stefan O. Schönland, MD, Kihyun Kim, MD, Vaishali Sanchorawala, MD, Heather J Landau, MD, Fiona Kwok, FRACP,FRCPA,MBBS, Kenshi Suzuki, MD PhD, Raymond L Comenzo, MD, Deborah Berg, RN, MSN, Guohui Liu, PhD, Douglas V. Faller, MD PhD, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 139.

https://doi.org/10.1182/blood-2019-124409

Published: 2019

Journal Articles

What Does AL Amyloidosis Look like in the Era of Mass Spectrometry Typing?

Blood (2017) 130 (Supplement 1): 4353.

https://doi.org/10.1182/blood.V130.Suppl_1.4353.4353

Published: 2017

Journal Articles

Orthotopic Heart Transplant Facilitated Autologous Hematopoietic Stem Cell Transplantation in Light-Chain Amyloidosis

Rammurti T Kamble, MD, Gloria Obi, PhD, Audrey Scholoff, MSN, George Carrum, MD, Lawrence Rice, MD, Arvind Bhimrajan, Jerry Estep

Blood (2015) 126 (23): 5364.

https://doi.org/10.1182/blood.V126.23.5364.5364

Published: 2015

Journal Articles

Orthotopic Heart Transplant Facilitated Autologous Hematopoietic Stem Cell Transplantation in Light-Chain Amyloidosis

Rammurti Kamble, MD, George Carrum, MD, Lawrence Rice, MD, John J. McCarthy, MD, Kelty R. Baker, MD, Carlos A. Ramos, MD, Horacio Adrogue, MD, Jerry Estep, MD

Blood (2011) 118 (21): 4489.

https://doi.org/10.1182/blood.V118.21.4489.4489

Published: 2011

Journal Articles

Left Atrium Enlargement Is An Independent Predictor of Overall Mortality In Patients with Cardiac AL Amyloidosis.

Dania Mohty, Philippe Pibarot, Nicole Darodes, Benedict Tanguy, David Lavergne, Najmeddine Echahidi, Patrice Virot, Dominique Bordessoule, Arnaud Jaccard

Blood (2010) 116 (21): 4621.

https://doi.org/10.1182/blood.V116.21.4621.4621

Published: 2010

Journal Articles

A Pilot Study of Pomalidomide and Dexamethasone in Previously Treated Light Chain Amyloidosis Patients.

Blood (2009) 114 (22): 3854.

https://doi.org/10.1182/blood.V114.22.3854.3854

Published: 2009

Journal Articles

Retrospective Study of the Efficacy of Bortezomib in Primary Systemic Amyloidosis.

Francis Buadi, MD, Martha Q. Lacy, MD, Angela Dispenzieri, M.D., Shaji Kumar, Suzanne Hayman, MD, Kristen E Detweiler Short, R.N., C.N.P., David Dingli, M.D., PhD., Steven R. Zeldenrust, M.D., Ph.D., Philip R. Greipp, MD, John A. Lust, MD, PhD, Stephen J. Russell, MD, PhD, Robert Kyle, M.D., Vincent Rajkumar, MD, Morie A Gertz, MD

Blood (2009) 114 (22): 4953.

https://doi.org/10.1182/blood.V114.22.4953.4953

Published: 2009

Journal Articles

Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity.

Jeffrey A Zonder, MD, Vaishali Sanchorawala, MD, Rachel M. Snyder, PhD, Jeffrey Matous, MD, Howard Terebelo, MD, Nalini Janakiraman, MD, Markus Y Mapara, MD, PhD, Silvana Lalo, MBA, Nishant Tageja, MD, Craig Webb, PhD, David Monsma, PhD, Catherine Sellers, RN, Judith Abrams, Statistician, Cristina Gasparetto, MD

Blood (2009) 114 (22): 746.

https://doi.org/10.1182/blood.V114.22.746.746

Published: 2009

Journal Articles

A Novel Prognostic Staging System for Light Chain Amyloidosis (AL) Incorporating Markers of Plasma Cell Burden and Organ Involvement.

Shaji Kumar, MD, Angela Dispenzieri, MD, Martha Q. Lacy, MD, Suzzane Hayman, MD, Francis Buadi, MD, Steven R. Zeldenrust, M.D., Ph.D., Nelson Leung, M.D., Marina Ramirez-Alvarado, Ph.D, Robert A Kyle, M.D., S. Vincent Rajkumar, MD, Morie A. Gertz, MD

Blood (2009) 114 (22): 2797.

https://doi.org/10.1182/blood.V114.22.2797.2797

Published: 2009

Journal Articles

The Prevalence of Abnormal Coagulation Parameters in Patients with Newly Diagnosed Primary Systemic Amyloidosis and Its Impact on Outcome

Tow Shung Tan, MD, Angela Dispenzieri, MD, Rajiv Pruthi, MBBS, Martha Q. Lacy, MD, Suzanne R. Hayman, MD, Francis K. Buadi, MD, Steven R. Zeldenrust, Robert A. Kyle, MD, S. Vincent Rajkumar, MD, Morie A. Gertz, MD, Shaji Kumar, MD

Blood (2008) 112 (11): 5114.

https://doi.org/10.1182/blood.V112.11.5114.5114

Published: 2008

Journal Articles

Osteopontin Predicts for Survival and Cystatin C-Based Estimated GFR Predicts for Renal Response to Therapy in Patients with Primary Systemic Amyloidosis

Evangelos Terpos, Efstathios Kastritis, Evelina Charitaki, Michalis Michail, Georgios Boutsikas, Eurydiki Michalis, Sosana Delimpasi, Marie-Christine Kyrtsonis, Meletios A. Dimopoulos

Blood (2008) 112 (11): 2731.

https://doi.org/10.1182/blood.V112.11.2731.2731

Published: 2008

Journal Articles

Phase I/II Study of Lenalidomide, Intermediate Dose Dexamethasone and Low Dose Cyclophosphamide (RDC) for the Treatment of Patients with Primary Systemic Amyloidosis (AL).

Efstathios Kastritis, Flora Zagouri, Maria Roussou, Magdalini Migkou, John Boletis, Theofanis Apostolou, Meletios A. Dimopoulos

Blood (2008) 112 (11): 1734.

https://doi.org/10.1182/blood.V112.11.1734.1734

Published: 2008

Journal Articles

Long Term Follow-up of Patients with Immunoglobulin Light Chain Amyloidosis Treated with Lenalidomide and Dexamethasone.

Angela Dispenzieri, Martha Lacy, MD, Stephen R. Zeldenrust, Suzanne R. Hayman, MD, Shaji K. Kumar, John A. Lust, MD, PhD, Jake Allred, S. Vincent Rajkumar, Philip R. Greipp, MD, Kristina Laumann, Stephen Russell, Francis Buadi, Thomas E Witzig, Morie A Gertz

Blood (2008) 112 (11): 1737.

https://doi.org/10.1182/blood.V112.11.1737.1737

Published: 2008

Journal Articles

Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis.

Tow-Shung Tan, MD, Angela Dispenzieri, MD, Martha Q. Lacy, MD, Suzanne R. Hayman, MD, Francis K. Buadi, MD, Steven R. Zeldenrust, MD, John A. Lust, MD, Stephen J. Russell, MD, David Dingli, MD, Philip R. Greipp, MD, Robert A. Kyle, MD, S. Vincent Rajkumar, MD, Morie A. Gertz, MD, Shaji Kumar, MD

Blood (2007) 110 (11): 3608.

https://doi.org/10.1182/blood.V110.11.3608.3608

Published: 2007

Journal Articles

14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).

Alan H. Bryce, MD, Rhett Ketterling, MD, Morie Gertz, MD, Steve Zeldenrust, MD, Martha Lacy, MD, Shaji Kumar, MD, Suzanne Hayman, MD, Francis Buadi, MD, Phillip Greipp, MD, John Lust, MD, Vincent Rajkumar, MD, Rafael Fonseca, MD, David Dingli, MD, Stephen Russell, MD, Robert Kyle, MD, Angela Dispenzieri, MD

Blood (2007) 110 (11): 2477.

https://doi.org/10.1182/blood.V110.11.2477.2477

Published: 2007

Journal Articles

Day 15 Dendritic Cell Recovery Predicts Overall Survivial after Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma.

Mustaqeem A. Siddiqui, MD, Svetomir N. Markovic, MD, Wendy K. Nevala, William Morice, MD, David J. Inwards, MD, Stephen M. Ansell, MD, Ivana N. Micallef, MD, Patrick B. Johnston, MD, Luis Porrata, MD

Blood (2007) 110 (11): 5009.

https://doi.org/10.1182/blood.V110.11.5009.5009

Published: 2007

Journal Articles

Increased Osteoprotegerin Levels in Response to Increased Bone Resorption in AL Amyloidosis: Comparisons with Bone Remodeling of Multiple Myeloma.

E. Kastritis, MD, Meletios Athanasios Dimopoulos, MD, M. Mihail, MD, E. Mihali, MD, M.C. Kyrtsonis, MD, S. Delimpassi, MD, E. Katodritou, MD, N. Anagnostopoulos, MD, G. Kokkini, MD, K. Zervas, MD, K. Anargyrou, MD, P. Panagiotidis, MD, E. Terpos, MD

Blood (2007) 110 (11): 3528.

https://doi.org/10.1182/blood.V110.11.3528.3528

Published: 2007

Journal Articles

Clinical Characteristics and Outcome of Primary AL Amyloidosis in Greece.

Michalis Michail, MD, Efstathios Kastritis, MD, Sossana Delimpassi, MD, Marie Christine Kyrtsonis, MD, Evridiki Michali, MD, Nicolaos Anagnostopoulos, MD, Konstantinos Zervas, MD, Eirini Katodritou, MD, Panagiotis Panagiotidis, MD, Natalia Tzenou, Gerassimos Pangalis, MD, Meletios Athanasios Dimopoulos, MD

Blood (2007) 110 (11): 4729.

https://doi.org/10.1182/blood.V110.11.4729.4729

Published: 2007

Journal Articles

Serum Uric Acid Is a Novel Prognostic Factor in Patients with Primary Systemic Amyloidosis.

Shaji K. Kumar, MD, Angela Dispenzieri, MD, Martha Q. Lacy, MD, Suzanne R. Hayman, MD, Nelson Leung, MD, Steven R. Zeldenrust, MD, PhD, Francis K. Buadi, MD, Robert A. Kyle, MD, Vincent Rajkumar, MD, Morie A. Gertz, MD

Blood (2007) 110 (11): 658.

https://doi.org/10.1182/blood.V110.11.658.658

Published: 2007

Journal Articles

Prognostic Value of Serum Lactate Dehydrogenase (LDH) in Patients with Primary Systemic Amyloidosis Undergoing Stem Cell Transplantation.

Shaji Kumar, MD, Martha Q. Lacy, MD, Angela Dispenzieri, MD, Suzanne Hayman, MD, Francis K. Buadi, MD, David Dingli, MD, Mark R. Litzow, MD, Morie A. Gertz, MD

Blood (2007) 110 (11): 2871.

https://doi.org/10.1182/blood.V110.11.2871.2871

Published: 2007

NARROW

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

What Does AL Amyloidosis Look like in the Era of Mass Spectrometry Typing?

Orthotopic Heart Transplant Facilitated Autologous Hematopoietic Stem Cell Transplantation in Light-Chain Amyloidosis

Orthotopic Heart Transplant Facilitated Autologous Hematopoietic Stem Cell Transplantation in Light-Chain Amyloidosis

Left Atrium Enlargement Is An Independent Predictor of Overall Mortality In Patients with Cardiac AL Amyloidosis.

A Pilot Study of Pomalidomide and Dexamethasone in Previously Treated Light Chain Amyloidosis Patients.

Retrospective Study of the Efficacy of Bortezomib in Primary Systemic Amyloidosis.

Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity.

A Novel Prognostic Staging System for Light Chain Amyloidosis (AL) Incorporating Markers of Plasma Cell Burden and Organ Involvement.

The Prevalence of Abnormal Coagulation Parameters in Patients with Newly Diagnosed Primary Systemic Amyloidosis and Its Impact on Outcome

Osteopontin Predicts for Survival and Cystatin C-Based Estimated GFR Predicts for Renal Response to Therapy in Patients with Primary Systemic Amyloidosis

Phase I/II Study of Lenalidomide, Intermediate Dose Dexamethasone and Low Dose Cyclophosphamide (RDC) for the Treatment of Patients with Primary Systemic Amyloidosis (AL).

Long Term Follow-up of Patients with Immunoglobulin Light Chain Amyloidosis Treated with Lenalidomide and Dexamethasone.

Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis.

14q32 Abnormalities and 13q Deletions Are Common in Primary Systemic Amyloidosis Using Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg-FISH).

Day 15 Dendritic Cell Recovery Predicts Overall Survivial after Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma.

Increased Osteoprotegerin Levels in Response to Increased Bone Resorption in AL Amyloidosis: Comparisons with Bone Remodeling of Multiple Myeloma.

Clinical Characteristics and Outcome of Primary AL Amyloidosis in Greece.

Serum Uric Acid Is a Novel Prognostic Factor in Patients with Primary Systemic Amyloidosis.

Prognostic Value of Serum Lactate Dehydrogenase (LDH) in Patients with Primary Systemic Amyloidosis Undergoing Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only